Scholarship Grants, Financial Results, and Stock Price Movements - Research Report on Amgen, HCA, Allergan, Teva, and Novartis PR Newswire NEW YORK, November 12, 2013 NEW YORK, November 12, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting Amgen, Inc. (NASDAQ: AMGN), HCA Holdings Inc. (NYSE: HCA), Allergan, Inc. (NYSE: AGN), Teva Pharmaceutical Industries Ltd. (ADR) (NYSE: TEVA), and Novartis AG (ADR) (NYSE: NVS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Amgen, Inc. Research Report On November 7, 2013, The Amgen Foundation, the philanthropic arm of Amgen, Inc. (Amgen), announced $2.5 million in new grants for the Amgen Biotech Experience, a science education program, bringing the total committed to nearly $8 million since the program's inception in 1990. According to the Company, The Amgen Biotech Experience provides real-world biotech lab experience to middle and high schools in Amgen's U.S. and United Kingdom (U.K.) communities and will engage more than 50,000 students in 2013. In addition, Amgen informed that it has named the Education Development Center, Inc., a global nonprofit organization that creates learning opportunities around the world, as Program Office to oversee the program's implementation and facilitate its continued development. The Full Research Report on Amgen, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/e96b_AMGN] -- HCA Holdings Inc. Research Report On November 5, 2013, HCA Holdings Inc. (HCA) reported its Q3 2013 financial results. The Company's revenues increased 4.9% YoY to c.$8.5 billion during the quarter. Net income attributable to HCA was $365 million or $0.79 per diluted share in Q3 2013, compared to net income attributable to HCA of $360 million or $0.78 per diluted share in Q3 2012. Commenting on the results, HCA Chairman and CEO, Richard M. Bracken, said, "We are pleased with the results of the third quarter. The Company's many clinical and operating initiatives continue to position our facilities to effectively compete in this changing healthcare environment." HCA expects its adjusted EBITDA for full-year 2013 to be near the upper-end of its previously issued guidance range of $6.25 billion to $6.50 billion. The Full Research Report on HCA Holdings Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/be59_HCA] -- Allergan, Inc. Research Report On November 5, 2013, Allergan, Inc. (Allergan) reported the results of a survey conducted by the Company and endorsed by the Women's Health Foundation. The survey found that nearly seven out of ten (69%) American women ages 45 or older may not recognize that passing urine more than eight times a day may be a signal of a bladder health problem. Allergan added that Bladder health issues are estimated to affect approximately 45% of the world's population ages 20 or older, yet according to the survey, there are women that have yet to learn about their bladders. Allergan also informed that as per the findings of the survey, almost two-thirds of American women ages 45 or older have never had a discussion about their bladder health with a physician. Missy Lavender, Founder and Executive Direct of Women's Health Foundation, said, "The results of the survey are of significant concern to me because while many bladder conditions, like overactive bladder, are common, they are by no means normal. Women should not have to settle for living with them as there are treatment options available." The Full Research Report on Allergan, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/182a_AGN] -- Teva Pharmaceutical Industries Ltd. (ADR) Research Report On October 31, 2013, Teva Pharmaceutical Industries Ltd. (ADR) (Teva) reported its Q3 2013 financial results. The Company's net revenues increased 1.7% YoY to $5.1 billion during the quarter. Net income attributable to Teva was $711 million or $0.84 per diluted share in Q3 2013 compared to net loss attributable to Teva of $79 million or $0.09 per diluted share in Q3 2012. Commenting on the results, Eyal Desheh, Acting President and CEO of Teva, said, "Teva's leadership and Board of Directors remain committed to executing on our strategy and diligently implementing changes which we believe will ensure the growth of our business. During the quarter we had six successful generic product launches in the U.S. alone, and are pleased that our generic business continues to benefit from a long-term, sustainable and profitable growth. We are also satisfied with the performance of our Global Specialty Medicines business and OTC joint venture." The Full Research Report on Teva Pharmaceutical Industries Ltd. (ADR) - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/e3a3_TEVA] -- Novartis AG (ADR) Research Report On November 7, 2013, Novartis AG's (ADR) (Novartis) stock declined 1.31%, ending the day at $76.89. Over the previous three trading sessions, shares of Novartis declined 1.93%, compared to the S&P 500 which declined 1.18% during the same period. The Full Research Report on Novartis AG (ADR) - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/9b6d_NVS] ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. SOURCE Analysts' Corner Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
Scholarship Grants, Financial Results, and Stock Price Movements - Research Report on Amgen, HCA, Allergan, Teva, and Novartis
Press spacebar to pause and continue. Press esc to stop.